Therapy Detail

Therapy Name Panobinostat
Synonym
Therapy Description

Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Panobinostat Farydak LBH589 HDAC Inhibitor 35 Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12A multiple myeloma sensitive Panobinostat Preclinical Actionable In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356). 19490892 22693356
Unknown unknown rhabdoid cancer not applicable Panobinostat Preclinical - Cell line xenograft Actionable In a preclinical study, Farydak (panobinostat) treatment of rhabdoid cancer cell lines in culture resulted in cell cycle arrest and cell differentiation and in cell line xenograft models, inhibition of tumor growth and a decrease in tumor size (PMID: 26920892). 26920892
Unknown unknown colon cancer not applicable Panobinostat Preclinical Actionable In a preclinial study, Faridak (panobinostat) enhanced the cytotoxicity of TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, in colon cancer cell lines (PMID: 21965751). 21965751
Clinical Trial Phase Therapies Title Recruitment Status
NCT02506959 Phase II Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Recruiting
NCT02717455 Phase I Panobinostat Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma Recruiting
NCT01032148 Phase I Panobinostat Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma Terminated
NCT02032810 Phase I Panobinostat Ipilimumab Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Active, not recruiting
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed
NCT02722941 Phase II Panobinostat Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) Recruiting
NCT01321346 Phase I Cytarabine Panobinostat A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed
NCT01169636 Phase Ib/II Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma Completed
NCT00946647 Phase II Panobinostat Azacitidine A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Active, not recruiting
NCT02720510 Phase II Panobinostat Bortezomib + Dexamethasone + Lenalidomide A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Terminated
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Not yet recruiting